标题：Research Grade Bebtelovimab 对照抗体,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/7162.html
名称：Research Grade Bebtelovimab对照抗体
别名：Bebtelovimab对照抗体，LY-CoV1404, LY3853113, SARS-like Coronaviruses
货号：DVV00319
适用物种：SARS-CoV-2 (2019-nCoV)
寄主物种：Human
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG1, lambda2
应用：Research Grade Biosimilar
UniProt：P0DTC2-2
靶点：Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
产品购买联系方式：027-65279366 /18162686757
邮箱：biolab-reagents@atagenix.com
QQ：2663991332
参考文献：
Bebtelovimab. PMID: 35230755
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. PMID: 33972947
Bebtelovimab in the Real World: Promise and Fulfillment. PMID: 36124710
Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest. PMID: 36003828
COVID-19 update: Bebtelovimab EUA withdrawn. PMID: 36651898
COVID-19 update: Resistance to bebtelovimab. PMID: 36397193
An EUA for bebtelovimab for treatment of COVID-19. PMID: 35294426
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System. PMID: 36438619
Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. PMID: 35939386
Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants. PMID: 36756927
SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis. PMID: 37701439
Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era. PMID: 36324319
Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5. PMID: 37072054
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. PMID: 35714668
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic. PMID: 36174596
Serious Infusion Reactions in Two Adolescents Receiving Bebtelovimab. PMID: 36476524
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. PMID: 35848574
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. PMID: 36124696
Effectiveness of Bebtelovimab Against Hospitalization and Death From the Omicron BA.4/BA.5 and BQ.1/BQ.1.1 Subvariants. PMID: 37414096
Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19. PMID: 37313067
The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis. PMID: 37085048
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch. PMID: 36213724
Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID-19 infection at an ambulatory cancer center. PMID: 38191852
Federal Government Buys Thousands of Bebtelovimab Doses. PMID: 35315904
Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants. PMID: 36992294
Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era. PMID: 37115780
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. PMID: 37085220
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab. PMID: 35863364
COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge. PMID: 36228295
Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. PMID: 36077159
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. PMID: 36788246
Current Effective Therapeutics in Management of COVID-19. PMID: 35807123
Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review. PMID: 37129306
Outpatient Management of COVID-19: A Primer for the Dermatologist. PMID: 36035078
Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review. PMID: 37719798
Update on COVID-19 Therapy in Pediatric Age. PMID: 36558963
Antibody evasion properties of SARS-CoV-2 Omicron sublineages. PMID: 35240676
Colitis After SARS-CoV-2 Infection. PMID: 35928392
Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron. PMID: 37708028
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study. PMID: 37011399
Therapeutic monoclonal antibodies for COVID-19 management: an update. PMID: 35604379